Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between lower urinary tract symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sex Med. 2009;6(8):2299-2304.
Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637-649.
Orabi H, Albersen M, Lue TF. Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. Int J Impot Res. 2011;23(3):99-108.
Kaminetsky J. Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin. 2006;22(12):2497-2506.
McVary K, Foley KA, Long SR, Sander S, Curtice TG, Shah H. Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction. Curr Med Res Opin. 2008;24(3):775-784.
McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332(7541):589-592.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326.
Barry MJ, Fowler FJ Jr, O'Leary MP, et al; Measurement Committee of the American Urological Association. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557.
Uroxatral [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2011.
Flomax [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2011.
Cardura [package insert]. New York, NY: Pfizer Inc; 2009.
Hytrin [package insert]. North Chicago, IL: Abbott Laboratories; 2009.
Avodart [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
Proscar [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2012.
Viagra [package insert]. New York, NY: Pfizer Inc; 2010.
Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
Levitra [package insert]. Wayne, NJ: Bayer AG; 2011.
Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials [review]. BMC Urol. 2002;2:14.
Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int. 2005;95(suppl 4):29-36.
Laydner HK, Oliveira P, Oliveira CR, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review [review]. BJU Int. 2011;107(7):1104-1109.
Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63(4):709-715.
McConnell JD, Bruskewitz R, Walsh P, et al; Finasteride Long-term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563.
Porst H, Kim ED, Casabé AR, et al; LVHJ Study Team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60(5):1105-1113.
Kaplan SA. Side effects of alpha-blocker use: retrograde ejaculation. Rev Urol. 2009;11(suppl 1):S14-S18.
Laborde EE, McVary KT. Medical management of lower urinary tract symptoms. Rev Urol. 2009;11(suppl 1):S19-S25.
Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [review]. Med Clin North Am. 2011;95(1):87-100.
Hwang TI, Lin YC. The relationship between hypogonadism and erectile dysfunction. Int J Impot Res. 2008;20(3):231-235.
Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Horm Res. 2009;37:108-122.
Amano T, Imao T, Takemae K, Iwamoto T, Nakanome M. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male. 2010;13(4):242-246.
Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008;11(2):57-61.
Karazindiyanoğlu S, Çayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008;11(3):146-149.
Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men [review]. World J Urol. 2008;26(4):359-364.
Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212(1):71-84.
Tamler R, Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. Postgrad Med. 2010;122(6):165-175.
Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):e157-e180.
Gore J, Rajfer J. Rising PSA during testosterone replacement therapy. Rev Urol. 2004;6(suppl 6):S41-S43.
Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.

It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity will address professional practice gaps in knowledge.

This program will contain discussion of investigational uses of pharmacologic and nonpharmacologic therapies. Individual clinical judgments should be used in all patient care decisions.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:

All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.

All staff at CogniMed Inc. have nothing to disclose.

Authors

Culley C. Carson III, MD

Rhodes Distinguished Professor and Chief of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Disclosures

Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: American Medical Systems; Auxilium Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline

Kevin T. McVary, MD

Professor of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

Disclosures

Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: Allergan, Inc.; Eli Lilly and Company; GlaxoSmithKline; the National Cancer Institute; the National Institutes of Health; Watson Pharmaceuticals, Inc.

CME

Medical Management of Comorbid BPH/LUTS and ED: Defining the Current Treatment Algorithm

Authors: Culley C. Carson III, MD; Kevin T. McVary, MD
CME Released: 6/19/2012
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/19/2013

Start Activity

Target Audience and Goal Statement

This activity has been designed to meet the educational needs of primary care physicians and urologists interested in the diagnosis and management of BPH/LUTS and ED.

Numerous epidemiologic studies have reported a strong association between benign prostatic hyperplasia–associated lower urinary tract symptoms (BPH/LUTS) and erectile dysfunction (ED) that is independent of age and other comorbidities.

LUTS and ED share common elements, including a multifactorial etiology and a possible biological link. Although a direct causal relationship is not yet established and the pathogenesis has not been completely elucidated, 4 pathophysiologic mechanisms potentially explain the relationship: an alteration in nitric oxide bioavailability, α1-adrenergic receptor hyperactivity, pelvic atherosclerosis, and sex hormones. These pathophysiologic pathways have various clinical implications for the management of ED and LUTS. Clinicians should recognize that all men seeking care for ED should be screened for complaints of BPH/LUTS and vice versa. Furthermore, sexual function should be assessed and discussed with the patient when choosing the appropriate management strategy for BPH/LUTS as well as when evaluating the patient's response to treatment.

Clinicians need to be aware of the potential positive and negative effects on sexual function of all medical therapies for BPH/LUTS. No single therapy for BPH/LUTS is superior to another; physicians should consider individual patient factors, efficacy, tolerability, treatment-related AEs (eg, retrograde ejaculation, diminished libido, ED), cost, and patient preference. Furthermore, men seeking help for BPH/LUTS should be assessed for various aspects of sexual dysfunction and informed about the impact of medication and surgery on sexual health.

Upon completion of this activity, participants should be able to:

Screen all men seeking care for benign prostatic hyperplasia–associated lower urinary tract symptoms (BPH/LUTS) for erectile dysfunction (ED) and vice versa
Examine with patients the adverse effect (AE) profile of each therapy when deciding the appropriate management strategy for BPH/LUTS and evaluating the patient's treatment response
Select therapeutic modalities with minimal AEs, particularly sexual AEs
Integrate BPH/LUTS and ED treatment goals to improve quality of life and optimize health outcomes

Disclosures

This activity will address professional practice gaps in knowledge.

This program will contain discussion of investigational uses of pharmacologic and nonpharmacologic therapies. Individual clinical judgments should be used in all patient care decisions.

All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.

All staff at CogniMed Inc. have nothing to disclose.

Authors

Culley C. Carson III, MD

Rhodes Distinguished Professor and Chief of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Disclosures

Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: American Medical Systems; Auxilium Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline

Kevin T. McVary, MD

Professor of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

Disclosures

Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: Allergan, Inc.; Eli Lilly and Company; GlaxoSmithKline; the National Cancer Institute; the National Institutes of Health; Watson Pharmaceuticals, Inc.

Accreditation Statements

For Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and CogniMed Inc. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

Statements of Credit will be provided electronically following activity participation and upon completion and submission of the evaluation online.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board. The estimated time to complete this activity is 1.5 hours; physicians should claim only those credits that reflect the time actually spent in the activity. This activity is an enduring material and consists of 3 interactive case studies. Successful completion is achieved by viewing the material, reflecting on its implications in your practice, and completing the assessment component. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

This program was developed to be released on Medscape.

The questions in this test-and-teach educational program are designed to test your current knowledge. After each question, you will see whether you answered the question correctly. The authors present referenced information to support the most appropriate answer choice and supplemental information (accessible by clicking on the links) to provide a more thorough understanding of the topic and the answers.

Page 1 of 8

CME Information

Print
Like Tweet

References

Disclaimer

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Authors

Culley C. Carson III, MD

Kevin T. McVary, MD

CME

Medical Management of Comorbid BPH/LUTS and ED: Defining the Current Treatment Algorithm

Target Audience and Goal Statement

Disclosures

Authors

Culley C. Carson III, MD

Kevin T. McVary, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Medical Management of Comorbid BPH/LUTS and ED: Defining the Current Treatment Algorithm